BCTXZ — BriaCell Therapeutics Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1610820 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jan 2026 | 0 | — | -7,531,266 | -7,221,820 | 33,594,454 | 29,903,628 | 3,380,646 |
| Oct 2025 | 0 | — | -8,322,943 | -8,197,565 | 13,075,050 | 2,714,012 | 3,724,646 |
| Apr 2025 | 0 | — | -6,328,255 | -6,126,902 | 17,001,798 | 12,460,253 | 5,060,645 |
| Jan 2025 | 0 | — | -7,169,443 | -6,291,420 | 9,363,567 | 5,013,654 | 6,136,676 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,755,093
Investing CF
$7,027,473
Financing CF
$47,805,428
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-127,174,949
Inventory
—
Receivables
$2,275,256
ST Investments
$0
EBIT TTM
$-29,211,602
Pretax Income TTM
$-28,137,978
Interest Exp TTM
$36,979
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jul 2024 | 0 | -33,330,076 | -4,791,466 | 5,872,261 | 8,557,193 | — | -24,126,128 |
| Jul 2023 | 0 | -23,272,264 | -20,302,394 | 27,163,577 | 30,940,758 | — | -23,744,860 |
| Jul 2022 | 0 | -15,285,553 | -26,838,903 | 42,577,041 | 32,248,109 | — | -12,484,376 |
| Jul 2021 | 0 | -6,972,344 | -13,816,200 | 58,043,762 | 30,372,041 | — | -7,750,188 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $949.47B | $1064.74 | — |
| JNJ | JOHNSON & JOHNSON | $554.09B | $230.18 | — |
| ABBV | AbbVie Inc. | $376.54B | $213.12 | — |
| MRK | Merck & Co., Inc. | $295.69B | $119.72 | — |
| AZN | ASTRAZENECA PLC | $290.30B | $187.19 | — |
News headlines (Yahoo Finance, 1h cache)
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
2026-05-26 11:30 · Yahoo
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
2026-05-22 11:30 · Yahoo
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
2026-05-15 11:30 · Yahoo
BriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies
2026-05-14 12:45 · Yahoo
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
2026-05-14 11:30 · Yahoo
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
2026-05-13 11:30 · Yahoo
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
2026-05-12 11:30 · Yahoo
BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
2026-05-07 11:30 · Yahoo
BriaCell Says FDA Clears Way For Bria-BRES+ Phase 1/2a Study
2026-05-06 11:56 · Yahoo
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
2026-05-06 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.